TY - JOUR
T1 - ErbB-2 signaling in advanced prostate cancer progression and potential therapy
AU - Miller, Dannah R.
AU - Ingersoll, Matthew A.
AU - Lin, Ming Fong
N1 - Funding Information:
This study was supported in part by the National 阀nstitutes of Health (CA88184), the US Department of Defense PCRP Grant (PC121645, and PC141559), the University of Nebraska Food for Health Grant, the University of Nebraska Medical Center Bridge Fund, the Bu 贀et Cancer Center Pilot Project Grant, the University of Nebraska Medical Center Cancer Biology Training Grant (T32CA009476), the University of Nebraska Medical Center Graduate Fellowship and the Purdue Pharma Scholars Award.
Publisher Copyright:
© 2019 Society for Endocrinology.
PY - 2018
Y1 - 2018
N2 - Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in US men. Most of these deaths are attributed to the development of castration-resistant (CR) PCa. ErbB-2 and ErbB family members have been demonstrated to contribute to the progression of this lethal disease. In this review, we focus on updating the role of ErbB-2 in advanced PCa progression and its regulation, including its regulation via ligand activation, miRNAs and protein phosphorylation. We also discuss its downstream signaling pathways, including AKT, ERK1/2 and STATs, involved in advanced PCa progression. Additionally, we evaluate the potential of ErbB-2, focusing on its protein hyper-phosphorylation status, as a biomarker for aggressive PCa as well as the effectiveness of ErbB-2 as a target for the treatment of CR PCa via a multitude of approaches, including orally available inhibitors, intratumoral expression of cPAcP, vaccination and immunotherapy.
AB - Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in US men. Most of these deaths are attributed to the development of castration-resistant (CR) PCa. ErbB-2 and ErbB family members have been demonstrated to contribute to the progression of this lethal disease. In this review, we focus on updating the role of ErbB-2 in advanced PCa progression and its regulation, including its regulation via ligand activation, miRNAs and protein phosphorylation. We also discuss its downstream signaling pathways, including AKT, ERK1/2 and STATs, involved in advanced PCa progression. Additionally, we evaluate the potential of ErbB-2, focusing on its protein hyper-phosphorylation status, as a biomarker for aggressive PCa as well as the effectiveness of ErbB-2 as a target for the treatment of CR PCa via a multitude of approaches, including orally available inhibitors, intratumoral expression of cPAcP, vaccination and immunotherapy.
KW - Cancer
KW - Castration-resistant prostate
KW - ErbB-2
KW - ErbB-2 regulation
KW - ErbB-2-targeting therapies
UR - http://www.scopus.com/inward/record.url?scp=85062809278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062809278&partnerID=8YFLogxK
U2 - 10.1530/ERC-19-0009
DO - 10.1530/ERC-19-0009
M3 - Review article
C2 - 31294537
AN - SCOPUS:85062809278
SN - 1351-0088
VL - 26
SP - R195-R209
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
IS - 4
ER -